Research progress of FAPI PET/CT in the diagnosis of malignant liver tumors.
10.3760/cma.j.cn501113-20230313-00110
- Author:
Xin Yue ZHANG
1
;
Wei HAN
1
;
Zhe Hao LYU
1
;
Hong Yue ZHAO
1
;
Peng FU
1
;
Chang Jiu ZHAO
1
Author Information
1. Department of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China.
- Publication Type:Journal Article
- Keywords:
(18)F-deoxyglucose;
Fibroblast activator protein inhibitor;
Hepatocellular carcinoma;
Intrahepatic cholangiocarcinoma;
Metastatic liver cancer;
Positron emission tomography and computed tomography
- MeSH:
Humans;
Positron Emission Tomography Computed Tomography;
Carcinoma, Hepatocellular;
Liver Neoplasms
- From:
Chinese Journal of Hepatology
2023;31(6):664-667
- CountryChina
- Language:Chinese
-
Abstract:
Malignant liver tumors have a high incidence and mortality rate. Therefore, it is of great significance to promptly learn about tumor advancement status through relevant examinations for patients' follow-up, diagnosis, and therapy as well as the improvement of the five-year survival rate. The primary lesions and intrahepatic metastases of malignant liver tumors have been better demonstrated in the clinical study with the use of various isotope-labeled fibroblast activating protein inhibitors because of their low uptake in liver tissues and high tumor/background ratio, which provides a new method for early diagnosis, precise staging, and radionuclide therapy. In light of this context, a review of the research progress of fibroblast-activating protein inhibitors for the diagnosis of liver malignant tumors is presented.
